Immunic, Inc. $IMUX Shares Acquired by Bank of America Corp DE

Key Points

• Bank of America significantly increased its Immunic stake by purchasing 143,689 additional shares in the first quarter, bringing its total holdings to 143,867 shares valued at approximately $160,000.
• Institutional investors and hedge funds collectively own 51.82% of Immunic, with several firms initiating or expanding positions during recent quarters.
• Analysts remain broadly positive, assigning Immunic a consensus “Buy” rating and a $47.25 average price target, despite the stock opening at $11.42 and the company continuing to report losses.

Bank of America Corp DE increased its stake in Immunic, Inc. (NASDAQ:IMUX - Free Report) by 80,724.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 143,867 shares of the company's stock after purchasing an additional 143,689 shares during the period. Bank of America Corp DE owned 1.06% of Immunic worth $160,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IMUX. ADAR1 Capital Management LLC acquired a new position in shares of Immunic during the first quarter valued at $33,000. Qube Research & Technologies Ltd bought a new position in shares of Immunic during the third quarter worth about $29,000. Focus Partners Wealth increased its holdings in shares of Immunic by 1.5% in the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company's stock worth $2,276,000 after acquiring an additional 39,063 shares during the period. Two Sigma Investments LP acquired a new position in Immunic during the 3rd quarter valued at about $52,000. Finally, Squarepoint Ops LLC boosted its stake in Immunic by 29.9% during the 4th quarter. Squarepoint Ops LLC now owns 352,875 shares of the company's stock valued at $188,000 after purchasing an additional 81,301 shares during the period. Institutional investors and hedge funds own 51.82% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. HC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Immunic in a research note on Thursday. Wedbush restated an "outperform" rating and issued a $45.00 target price on shares of Immunic in a research report on Thursday. Wall Street Zen raised Immunic from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. B. Riley Financial reduced their price target on Immunic from $40.00 to $27.00 and set a "buy" rating for the company in a research report on Friday, May 22nd. Finally, Wolfe Research started coverage on Immunic in a research note on Friday, May 22nd. They issued an "outperform" rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Immunic presently has a consensus rating of "Buy" and a consensus price target of $47.25.

Immunic Price Performance

NASDAQ IMUX opened at $11.42 on Friday. Immunic, Inc. has a 12 month low of $5.06 and a 12 month high of $17.43. The firm has a market capitalization of $155.77 million, a PE ratio of -2.61 and a beta of 1.41. The company's 50 day simple moving average is $14.68 and its 200 day simple moving average is $13.08.

Immunic (NASDAQ:IMUX - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($1.16) by $0.36. Sell-side analysts anticipate that Immunic, Inc. will post -3.71 earnings per share for the current fiscal year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

Want to see what other hedge funds are holding IMUX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunic, Inc. (NASDAQ:IMUX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.